Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal - Epi-Asthma

Study identifier:D2287R00155

ClinicalTrials.gov identifier:NCT05169619

EudraCT identifier:N/A

CTIS identifier:N/A

Recruiting

Official Title

Epi-Asthma: Prevalence and Characterisation of Asthma Patients According to Disease Severity in Portugal

Medical condition

asthma

Phase

N/A

Healthy volunteers

Yes

Study drug

-

Sex

All

Actual enrollment

7500

Study type

Observational

Age

18 Years - n/a

Date

Study Start Date: 30 Apr 2021
Estimated Primary Completion Date: 29 Dec 2023
Estimated Study Completion Date: 29 Dec 2023

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 May 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Faculdade de Medicina da Universidade do Porto - CINTESIS, Universidade do Minho - ICVS

Inclusion and exclusion criteria